A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial

By sjmartinez • June 22, 2024

McKetin R, Degan TJ, Saunders L, Nguyen L, Dore G, Shoptaw S, Farrell M, Degenhardt L, Kelly PJ, Turner A, Clare PJ, Dean OM, Arunogiri S, Colledge-Frisby S, Koeijers J, Goodman-Meza D, Sinclair B, Reid D, Hill H, Hayllar J, Christmass M, Cordaro F, Lundin R, Liaw W, Liu D, Holyoak E, Wu BT, Keygan J, Kontogiannis A, Palmer L, Morrison C, Wrobel A, Hyland B, Byrne M, Russell S, Zahra E, Berk M. A phase 3 randomised double-blind placebo-controlled trial of mirtazapine as a pharmacotherapy for methamphetamine use disorder: a study protocol for the Tina Trial. Trials. 2024 Jun 22;25(1):408. doi: 10.1186/s13063-024-08238-y. PMID: 38907288; PMCID: PMC11193254.

Tags: Addiction, Clinical Trial, depression, Infectious Diseases, Methamphetamine, Mirtazapine, pharmacotherapy, Psychiatry, Publications, sleep, substance use disorders, Treatment

Effect of inhaled interferon-β1a on SARS-CoV-2 diversity and evolution

Edelstein GE, Sass TN, Deo R, Glover OT, Boucau J, Jaganathan P, Chew KW, Giganti MJ, Hughes MD, Moser C, Javan AC, Fletcher CV, McCarthy[...]

Assessing mpox knowledge and sexual behaviours within high-risk populations in the Democratic Republic of the Congo

Lemaille C, Halbrook M, Merritt S, Anta Y, Lunyanga L, Mukadi PK, Hasivirwe Vakaniaki E, Kalonji T, Kenye M, Kacita C, Linsuke S, Bogoch II,[...]

β-Glucan chitosan particle provides cross-protection against multi-drug-resistant Candida auris

Singh S, Barbarino A, Youssef EG, Das Gupta K, Nabeela S, Gebremariam T, Alkhazraji S, Uppuluri P, Ostroff G, Ibrahim AS. β-Glucan chitosan particle provides[...]